A sarcoidosis patient developing psoriatic arthritis 18 years later: first description
Main Article Content
Keywords
Sarcoidosis, lung disease, pulmonary disease, granulomatous disease, psoriatic arthritis, psoriasis, rheumatic disease, autoimmunity
Abstract
.
References
2. Hu MK, Mathur A, Dempsey OJ. Pulmonary sarcoidosis: a clinical update. J R Coll Physicians Edinb. 2020 Sep;50(3):322-329. doi: 10.4997/JRCPE.2020.324.
3. Burnevich ES, Popova EN, Ponomarev AB, Nekrasova TP, Lebedeva MV, Filatova AL, Shchanitcyna EM, Ponomareva LA, Beketov VD, Bondarenko IB, Tanashchuk EL, Nikulkina EN, Moiseev SV. Autoimmune liver disease (primary biliary cholangitis/autoimmune hepatitis-overlap) associated with sarcoidosis (clinical cases and literature review). Ter Arkh. 2019 Mar 11;91(1):89-94. doi: 10.26442/00403660.2019.01.000036.
4. Korsten P, Tampe B, Konig MF, Nikiphorou E. Sarcoidosis and autoimmune diseases: differences, similarities and overlaps. Curr Opin Pulm Med. 2018 Sep;24(5):504-512. doi: 10.1097/MCP.0000000000000500.
5. Judson MA. Environmental Risk Factors for Sarcoidosis. Front Immunol. 2020 Jun 26;11:1340. doi: 10.3389/fimmu.2020.01340.
6. Cuchacovich R, Hagan J, Khan T, Richert A, Espinoza LR. Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature. Clin Rheumatol. 2011 Jan;30(1):133-7. doi: 10.1007/s10067-010-1577-1.
7. Kobak S, Semiz H. Ustekinumab-induced Sarcoidosis in a Patient with Psoriatic Arthritis. Curr Drug Saf. 2020;15(2):163-166. doi: 10.2174/1574886315666200316113312.
8. Christoforidou A, Goudakos J, Bobos M, Lefkaditis E, Vital V, Markou K. Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy. Am J Otolaryngol. 2013 May-Jun;34(3):268-72. doi: 10.1016/j.amjoto.2012.12.016.
9. Olivier A, Gilson B, Lafontaine S, Pautot JX, Bindi P. Sarcoïdose pneumo-rénale apparue sous anti-TNFα [Pulmonary and renal involvement in a TNFα antagonist drug-induced sarcoidosis]. Rev Med Interne. 2012 May;33(5):e25-7. French. doi: 10.1016/j.revmed.2011.03.336.
10. Wu C-H, Chung P-I, Wu C-Y, et al. Comorbid autoimmune diseases in patients with sarcoidosis: A nationwide case-control study in Taiwan. J Dermatol 2017; 44:423–430.
11. Yu M, Sandhu VK, Lezcano SD, et al. Sarcoidosis and systemic sclerosis: strange bedfellows. Case Rep Rheumatol 2017; 2017:7851652.; Carmi O, Berla M, Edelstein E, Levy Y. Coexisting systemic sclerosis-polymyositis and sarcoidosis: case report and review of the literature. J Clin Rheumatol 2018; 24:238–240.
12. Toussirot E', Aubin F. Paradoxical reactions under TNF-a blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open 2016; 2:e000239.
13. Jung JH, Kim J-H, Song GG. Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept. Z Rheumatol 2017; 76:372–374; Tchernev G, Patterson JW, Nenoff P, Horn LC. Sarcoidosis of the skin–a dermatological puzzle: important differential diagnostic aspects and guidelines for clinical and histopathological recognition. J Eur Acad Dermatol Venereol 2010; 24:125–137.
14. Korsten P, Sweiss NJ, Nagorsnik U, et al. Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab. Am J Kidney Dis 2010; 56:e17–e21.
15. Chopra A, Nautiyal A, Kalkanis A, Judson MA. Drug-induced sarcoidosis-like reactions (DISR). Chest 2018. Apr 14; pii: S0012-3692(18) 30640-8.
16. Amber KT, Bloom R, Mrowietz U, Hertl M (2015) TNF-α: a treatment target or cause of sarcoidosis? JEur AcadDermatol Venereol29:2104–2011.
17. PetrekM(2015)Personalizedmedicinein sarcoidosis: predict responders and nonresponders. Curr OpinPulmMed21:532–537.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
